Evidence map›Paper›PMID 33897943›Full record

ArticleOxidative medicine and cellular longevity2021

Deferasirox, an Iron-Chelating Agent, Improves Testicular Morphometric and Sperm Functional Parameters in a Rat Model of Varicocele.

M Rahmani, M Tavalaee, M Hosseini, A Eskandari, E Shaygannia, N Sadeghi, M N Nazem, P Gharagozloo, J R Drevet, M H Nasr-Esfahani

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. SilencingEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

M RahmaniDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0001-8036-0740
M TavalaeeDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0001-9954-964X
M HosseiniDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0002-1267-3494
A EskandariDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0002-1190-2902
E ShayganniaDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0003-0585-1413
N SadeghiDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0003-4388-4566
M N NazemDepartment of Basic Science, School of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran.ORCID https://orcid.org/0000-0001-7963-4935
P GharagozlooCellOxess LLC, 830 Bear Tavern Road, Ewing NJ 08628, USA.ORCID https://orcid.org/0000-0003-3955-3297
J R DrevetGReD Institute, Faculty of Medicine, INSERM-CNRS-Université Clermont Auvergne, France.ORCID https://orcid.org/0000-0003-3077-6558
M H Nasr-EsfahaniDepartment of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.ORCID https://orcid.org/0000-0003-1983-3435
Royan Institute · IRCellOxess (United States) · USCentre National de la Recherche Scientifique · FRShahid Bahonar University of Kerman · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Varicocele is characterized by testicular dysfunction that originates from hyperthermia and hypoxia, leading to defects in testicular tissue and altered spermatozoa structure and function. The varicocele testis is characterized by the presence of intracellular iron deposits that contribute to the associated oxidative stress. Therefore, we tested the hypothesis that administration of an iron-chelating agent, such as deferasirox (DFX), could potentially mitigate the consequences of varicocele on testicular tissue and spermatozoa. Using a well-established rat model of varicocele (VCL), we show that treatment with DFX partially improved the structure and function of the testis and spermatozoa. In particular, sperm motility was markedly restored whereas abnormal sperm morphology was only partially improved. No significant improvement in sperm count was observed that could be associated with the proapoptotic response observed following iron chelation treatment. No reduction in oxidative damage to spermatozoa was observed since lipid peroxidation and DNA integrity were not modified. This was suggested to be a result of increased oxidative stress. Finally, we also saw no indication of attenuation of the endoplasmic reticulum/unfolded protein (ER/UPR) stress response that we recently found associated with the VCL testis in rats.

Indexed as

AnimalsDeferasiroxDisease Models, AnimalHumansIron Chelating AgentsMaleRatsRats, WistarSperm MotilityTestisVaricoceleDeferasiroxIron Chelating Agents

Identifiers

PMID33897943
PMCPMC8052147
OpenAlexW3152755240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.